Melbourne merger for a united vision and stronger Victoria
Posted: 16 July 2024 We are delighted to announce that Committee for Melbourne and Melbourne Chamber of Commerce intend to come together to create a stronger voice to advocate for the future of Greater Melbourne. The expanded Committee…
Optiscan Receives Ethical Clearance for Breast Cancer Study
Posted: 16 July 2024 Optiscan Imaging Limited (ASX:OIL) (‘Optiscan’ or ‘The Company’) is pleased to announce that it has received ethical clearance from the Royal Melbourne Hospital Human Research Ethics Committee to undertake an in vivo clinical study…
Hub opens opportunities for new disease treatments
Posted: 16 July 2024 A new treatment that could potentially reverse or stop progression of traumatic brain injury will be developed at a new state-of-the-art biotechnology facility launched at La Trobe University. The $8 million Bio Innovation Hub,…
Florey biotech spin-out secures seed investment from Curie.Bio
Posted: 16 July 2024 Alkira Bio uses its proprietary LASEREDD® technology platform to discover therapeutic antibodies directed against previously out of reach targets, pioneering new possibilities for drug discovery. The seed financing from Curie.Bio recognises Alkira Bio’s advanced…
Cumming Global Centre for Pandemic Therapeutics awards AU$5 million in grant funding
Posted: 16 July 2024 Monash University researchers will develop a first of its kind inhaler device to conveniently treat respiratory viruses, while University of York researchers will screen 200 animal viruses to assess human pandemic risk and inform proactive…
Backing The Next Generation Of Life-Saving Treatments And Jobs
Posted: 16 July 2024 The Allan Labor Government is ensuring Victoria’s medical research sector can continue to drive nation-leading infectious disease treatments and develop new products, grow exports and create jobs – with the opening of the Medicines Manufacturing…
Immutep Reports Positive Results in First Line Head and Neck Squamous Cell Carcinoma Patients with Negative PD-L1 Expression
Posted: 16 July 2024 Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces positive results from Cohort B of the TACTI-003 (KEYNOTE-PNC-34) Phase…
New Medicines Manufacturing Innovation Centre opens: Monash accelerates medical innovation and development of life-saving treatments
Posted: 11 July 2024 Victorian Deputy Premier and Minister for Medical Research the Hon Ben Carroll today officially opened the newly built Medicines Manufacturing Innovation Centre (MMIC) within the heart of the Monash Technology Precinct, Clayton. Funded through…
Biotech Innovators Program
Posted: 9 July 2024 Closes: 22 July 2024 The Biotech Innovators Program is designed for Victorian based scientists, researchers, clinicians, SME’s and tech transfer professionals who are looking to build their research translation skills. Under the guidance of…
Professor Peter van Wijngaarden to become next Director and CEO of The Florey
Posted: 9 July 2024 After an extensive global search, Professor Peter van Wijngaarden has been named as the next Director and CEO of The Florey Institute of Neuroscience and Mental Health. Board Chair Mr Martin Adams said Professor van Wijngaarden…
Game-changing Peter Mac research destroys cancer-causing RNA
Posted: 4 July 2024 Peter Mac researchers have taken the first step towards designing rapid personalised cancer treatments by ‘cutting out’ disease-causing RNA. The findings, published in Nature Structural & Molecular Biology Journal, demonstrate how an innovative technology called…
Completion of Recruitment of First 26 Patients in Phase 2A ACCENT Trial
Posted: 4 July 2024 Amplia Therapeutics Limited (ASX: ATX), (“Amplia” or the “Company”), is pleased to announce that it has now recruited 26 patients in the Phase 2a stage of its clinical trial investigating narmafotinib in the treatment…
